ClinicalTrials.gg
RecruitingNCT07235514AMETIS 2Updated Sep 2, 2026

Anesthesia Management in Endovascular Therapy for Ischemic Stroke - 2

An interventional study of General Anesthesia and Procedural sedation in Ischemic Stroke, Anterior Cerebral Circulation and General Anesthesia, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 16 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
958
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 164 studies in Ischemic Stroke with a site in France — 56 open to participants now, 61 under way, 10 of them phase 3. Ischemic Stroke · France.

Planned enrollment
14th of 109
958 · median 186
Started
2026
with 8 others
No phase
58 of 164
23 open now
Primary completion
2029-06
later than 51 of 60 live
Registered
157th of 164
by date

Among the 164 studies in Ischemic Stroke with a site in France, this one is the 14th largest by planned enrollment of the 109 interventional ones that give a count, is one of 9 that started in 2026, is one of 58 with no phase, reaches primary completion later than 51 of the 60 other live ones, and was the 157th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

56 of the 164 studies in Ischemic Stroke with a site in France are open now. Recruiting first, the newest first:

50 more — sign in →

All 56 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Ischemic Stroke with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn what is the best anesthetic management in participants with severe stroke that require a medical intervention called mechanical thrombectomy (MT) done to open the occluded brain vessel.

The main question it aims to answer is:

  • Is general anesthesia (GA) better than procedural sedation (PS) for improving functional performance and decrease dependance in daily life 3 months after stroke?

GA (a non-arousable state induced by anesthetic medications that require respiratory assistance) or PS (a state of reduced arousal induced by lesser dose of anesthetic medications that do not require respiratory assistance) are both used for MT. GA enables strict immobility that could facilitate the conduct of MT but lessen blood pressure and blood flow in the brain. PS provides less drop in blood pressure but MT could be more difficult due to possible movement and breathing may be decreased.

Researchers will compare GA with PS to see which one is better for MT success and for the functional consequences of stroke.

Participants will be treated with GA or PS for the intervention of MT and will be followed by researchers during their hospital stay and asked by a telephone interview how is their functional status 3 months after stroke.

Read the detailed description

Mechanical thrombectomy (MT) has significantly improved the outcome of anterior circulation large vessel occlusion stroke. The MT procedure could require management by a dedicated anesthesia team to ensure safety and immobility of these frail patients, in order to quickly restore cerebral perfusion and prevent procedural complications. The anesthetic strategy (general anesthesia with tracheal intubation (GA) or procedural sedation with spontaneous ventilation (PS)) can impact the conduct of the procedure and influence the functional outcome. GA ensures immobility and airway control, but can alter blood pressure (BP). PS provides better control of BP but may be associated with respiratory failure and movements that could interfere with intra-arterial navigation.

Three European single-center randomized controlled trials (RCTs) found no difference between GA and PS for their respective primary endpoints. These three trials were pooled in an individual patient data meta-analysis that evaluated functional outcome (modified Rankin Scale mRS) at 3 months as the primary endpoint. 368 patients were included, and GA was associated with a better functional outcome (mean mRS score was 2.8 (95% CI, 2.5-3.1) in the GA group vs. 3.2 (95% CI, 3.0-3.5) in the PS group (difference, 0.43 [95% CI, 0.03-0.83])). The main limitations of this trial were 1) the small sample size (3 small single-center trials), 2/ a possible center effect with over-representation of one trial on the primary endpoint, and 3/ a highly selected population (exclusion of less severe patients (NIHSS\<10), stroke presentation > 8 hours and wake up stroke).

Two French multicenter RCTs have recently been published. The GASS trial included 345 patients in four centers with dedicated GA and PS protocols. There was no difference in the primary endpoint, which was functional independence (mRS 0 to 2) at three months (36% for PS vs. 38% for GA (RR, 0.91 [95% CI, 0.69 to 1.19], p = 0.47)). The AMETIS trial included 273 patients in 10 centers with no specified GA or PS protocol. There was no difference in the primary endpoint, which was a composite of functional independence at 3 months and absence of any peri-procedural and medical complications during the first 7 days. The median mRS was 3 (2-5) under GA vs. 3 (2-4) under PS; RR 0.80 [95% CI: 0.53 to 1.22]. GA was strongly associated with the occurrence of arterial hypotension (87.4% vs. 44.9% in the PS group).

However, 1) these multicenter trials had relatively small sample sizes, 2) the time of assessment of the primary outcome measure was highly variable in GASS, and 3) in AMETIS, the BP targets in the GA group were not met and there was heterogeneity in drug management under PS and GA.

These contradictory results reveal a persistent clinical equipoise regarding this important issue.

The AMETIS-2 trial will evaluate almost every patient with anterior circulation large vessel occlusion stroke eligible for MT in different French comprehensive stroke centers.

The trial protocol for PS and GA will use dedicated anesthetic and hemodynamic management protocols.

The primary outcome measure will use an ordinal shift analysis of the mRS score evaluated at 3 months as the primary endpoint.

To extend the effect analysis, functional independence, cognitive and quality of life assessment will be evaluated as secondary endpoints at 3 months.

We therefore hypothesize that, with a dedicated anesthetic protocol and strict hemodynamic control, GA will lead to a better long-term functional outcome after stroke.

03

Conditions studied

  • Ischemic Stroke
  • Anterior Cerebral Circulation
  • General Anesthesia
  • Procedural Sedation
  • Thrombectomy

Browse trials for

Keywords

  • Ischemic stroke
  • anterior circulation
  • mechanical thrombectomy
  • anesthetic strategy
  • general anesthesia
  • procedural sedation
  • functional outcome
  • large vessel occlusion stroke
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Acute ischemic stroke with an occlusion of the intracranial internal carotid artery and/or the proximal middle cerebral artery (M1-M2) with or without association of extracranial occlusion of the cervical internal carotid artery (tandem lesion)
  • Eligible for mechanical thrombectomy according to international guidelines
  • Informed and signed consent of patient, or if he is unable to consent the consent of patient's relative or emergency procedure in the absence of relative
  • National health insurance

Exclusion criteria

Exclusion Criteria:

  • Coma or altered vigilance defined as a score ≥ 2 on the level of consciousness 1A subscale of the NIHSS
  • Premorbid disability defined as a mRS > 2
  • Posterior circulation stroke
  • Associated cerebral hemorrhage
  • Stroke complicating another acute illness or postoperative stroke
  • Emesis at arrival in angiosuite
  • Allergy to anesthetic medication
  • Pregnant or breast-feeding women
  • Adult under the protection of the law
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
958 participants (estimated)

Study arms

  • Experimental
    General anesthesia

    General anesthesia with intubation and mechanical ventilation: ECG, SpO2 and BP. BP will be measured every 2 minutes Hyperglycemia (\>180mg/dL) and hypoglycemia (\<60mg/dL) should be treated (outside of the protocol) Systolic BP: 150 - 180mmHg with Diastolic BP \< 105mmHg Norepinephrine tartrate infusion or Nicardipine on a peripheral intravenous line or on a 3-way venous extender, as necessary EtCO2 35 - 45mmHg SpO2 above 94 %. Glycemia as needed End of procedure: Anesthesia will be immediately stopped and extubation should not be delayed. After the intervention, patients are transferred to the post anesthesia care unit and are then admitted to the stroke unit First 24 hours: SBP\<180mmHg, DBP\<110mmHg and MAP\>65mmHg, SpO2 \> 94 %, temperature \< 38°C, blood glucose 60 - 180mg/dL. Other aspects of monitoring are not modified by the protocol. 24-48h outside of the protocol: non-contrast brain CT or a brain MRI

    Procedure: General Anesthesia

  • Experimental
    Procedural sedation

    Procedural sedation with spontaneous ventilation: ECG, SpO2 and BP. BP will be measured every 2 minutes Hyperglycemia (\>180mg/dL) and hypoglycemia (\<60mg/dL) should be treated (outside of the protocol) Systolic BP: 150 - 180mmHg with Diastolic BP \< 105mmHg Norepinephrine tartrate infusion or Nicardipine on a peripheral intravenous line or on a 3-way venous extender, as necessary Breathing face mask: EtCO2 and oxygen as necessary SpO2 above 94 %. Glycemia as needed End of procedure: Procedural sedation will be immediately stopped. After the intervention, patients are transferred to the post anesthesia care unit and are then admitted to the stroke unit First 24 hours: SBP\<180mmHg, DBP\<110mmHg and MAP\>65mmHg, SpO2 \> 94 %, temperature \< 38°C, blood glucose 60 - 180mg/dL. Other aspects of monitoring are not modified by the protocol. 24-48h outside of the protocol: non-contrast brain CT or a brain MRI

    Procedure: Procedural sedation

Interventions

  • ProcedureGeneral Anesthesia

    In the general anesthesia (GA) group with tracheal intubation : Clinical target: unarousable state Standard preoxygenation, • Rapid sequence induction of GA will use intravenous Etomidate (0.2-0.3mg/Kg) or Ketamine (1-2mg/Kg) and Succinylcholine (1mg/Kg) or Rocuronium (1.2 mg/Kg) • Maintenance of GA will use intravenous Propofol (brain tissue target controlled infusion up to 4.0 µg/mL or up to 5.0 mg/kg/hr) or Sevoflurane (end-tidal concentration up to 2% (EtSevo)) and intravenous Remifentanil (brain tissue target controlled infusion up to 4.0 ng/mL) Movement despite unarousable state: NMBA as needed

    Also known as: GA

  • ProcedureProcedural sedation

    In the procedural sedation group with spontaneous ventilation : Clinical target: alert and "confortable" i.e. minimal to moderate sedation level * Subcutaneous local anesthesia with Lidocaine 10mg/mL (maximum 10mL) * Intravenous Remifentanil as necessary to achieve the sedation clinical target (brain tissue target controlled infusion up to 2.0 ng/mL). Propofol could be added as necessary (brain tissue target controlled infusion up to 3.0 µg/mL or 2.0 mg/kg/hr). The lightest sedation level allowing the intervention has to be sought.

    Also known as: PS

06

What researchers measure

Primary outcomes

  1. modified Rankin Scale

    modified Rankin Scale, that range from 0 to 6: 0, no neurologic deficit; 1, no clinically significant disability; 2, slight disability; 3, moderate disability requiring some help; 4, moderately severe disability; 5, severe disability; 6, death \> measured centrally by a blinded evaluator

    Time frame: Day 90 after the stroke

Secondary outcomes

  1. Functional independence = key secondary outcome

    Functional independence defined as a score of 0-2 on the rating of the modified Rankin Scale measured centrally by a blinded evaluator. This will be analyzed as a dichotomized measure

    Time frame: Day 90 after the stroke

  2. Modified Treatment in Cerebral Infarction scale at the end of thrombectomy (mTICI).

    To assessed efficacy of GA vs PS

    Time frame: At day 1 (end of the thrombectomy procedure)

  3. Good quality of reperfusion defined as a mTICI score of 2b-3

    To assessed efficacy of GA vs PS

    Time frame: At day 1 (end of the thrombectomy procedure)

  4. Excellent quality of reperfusion defined as a mTICI score of 2c-3

    To assessed efficacy of GA vs PS

    Time frame: At day 1 (end of the thrombectomy procedure)

  5. National Institute of Health Stroke Scale (NIHSS)

    To assessed efficacy of GA vs PS

    Time frame: At day 1 after the thrombectomy procedure

  6. National Institute of Health Stroke Scale (NIHSS)

    To assessed efficacy of GA vs PS

    Time frame: At day 7 after the thrombectomy procedure

  7. Length of stay in stroke-unit and hospital

    To assessed efficacy of GA vs PS

    Time frame: At day 90 after the thrombectomy procedure

  8. moderate recovery defined as a score of 0-3 on the rating of the modified Rankin Scale

    To assessed efficacy of GA vs PS

    Time frame: At day 90 after the thrombectomy procedure

  9. Utility-weighted modified Rankin scale

    To assessed efficacy of GA vs PS

    Time frame: At day 90 after the thrombectomy procedure

  10. Barthel index

    To assessed efficacy of GA vs PS

    Time frame: At day 90 after the thrombectomy procedure

  11. Montreal Cognitive Assessment (MOCA)

    To assessed efficacy of GA vs PS

    Time frame: At day 90 after the thrombectomy procedure

  12. Stroke Specific Quality Of Life scale (SSQOL)

    To assessed efficacy of GA vs PS

    Time frame: At day 90 after the thrombectomy procedure

  13. Per-interventional arterial dissection or perforation defined as a flow-limiting tear or flap in the arterial wall or arterial extravasation of contrast media

    To assessed safety of GA vs PS

    Time frame: At the end of the thrombectomy procedure

  14. Per-interventional embolization in another territory defined as a new (not present on the first angiogram) arterial occlusion outside of the middle cerebral artery territory

    To assessed safety of GA vs PS

    Time frame: At the end of the thrombectomy procedure

  15. Procedural hypotension, hypertension, blood pressure variability, hypoxemia and aspiration (Yes or No)

    To assessed safety of GA vs PS

    Time frame: At the end of the thrombectomy procedure

  16. Hemodynamic protocol adherence

    To assessed safety of GA vs PS

    Time frame: At day 1 after the thrombectomy procedure

  17. Post-interventional groin hematoma defined as an accumulation of blood at the puncture site requiring evacuation, transfusion, or extended hospital stay

    To assessed safety of GA vs PS

    Time frame: At day 7 after the thrombectomy procedure

  18. Intracranial hemorrhage

    To assessed safety of GA vs PS

    Time frame: At day 1 after the thrombectomy procedure

  19. medical complications (could be evaluated before day 7 if the patient quit the hospital)

    To assessed safety of GA vs PS

    Time frame: At day 7 after the thrombectomy procedure

  20. Mortality

    To assessed safety of GA vs PS

    Time frame: At day 7 after the thrombectomy procedure

  21. Mortality

    To assessed safety of GA vs PS

    Time frame: At day 90 after the thrombectomy procedure

07

Study locations

7 of 16 sites recruiting
  • Le Centre Hospitalier Universitaire d'Angers
    Angers, 49933, France
    Active, not recruiting

    Not enrolling at this site.

  • Le Centre Hospitalier Universitaire Morvan de Brest de Brest
    Brest, 29200, France
    Not yet recruiting
  • CHU de Clermont-Ferrand
    Clermont-Ferrand, France
    Recruiting
  • Le centre hospitalier universitaire de Lille
    Lille, 59000, France
    Recruiting
  • Les Hospices Civils de Lyon
    Lyon, 69229, France
    Recruiting
  • L'Assistance Publique - Hôpitaux de Marseille
    Marseille, France
    Recruiting
  • Le centre hospitalier universitaire de Montpellier
    Montpellier, 34295, France
    Not yet recruiting
  • Le Centre Hospitalier Universitaire de Nantes
    Nantes, 44093, France
    Recruiting
  • L'Assistance Publique - Hôpitaux de Paris
    Paris, 75610, France
    Recruiting
  • Le Centre Hospitalier Universitaire de La Réunion
    Saint-Denis, 97400, France
    Not yet recruiting
  • Le Centre Hospitalier Universitaire de Saint-Etienne
    Saint-Etienne, 42055, France
    Not yet recruiting
  • Le Centre Hospitalier Universitaire de Strasbourg
    Strasbourg, 67200, France
    Active, not recruiting

    Not enrolling at this site.

  • L'hôpital Foch
    Suresnes, 92151, France
    Not yet recruiting
  • Le Centre Hospitalier Universitaire de Bordeaux
    Talence, 33404, France
    Active, not recruiting

    Not enrolling at this site.

  • Le Centre Hospitalier Universitaire de Toulouse
    Toulouse, 31059, France
    Recruiting
  • Le Centre Hospitalier Universitaire de Tours
    Tours, 37044, France
    Not yet recruiting
08

References and documents

Publications

  • Schonenberger S, Henden PL, Simonsen CZ, Uhlmann L, Klose C, Pfaff JAR, Yoo AJ, Sorensen LH, Ringleb PA, Wick W, Kieser M, Mohlenbruch MA, Rasmussen M, Rentzos A, Bosel J. Association of General Anesthesia vs Procedural Sedation With Functional Outcome Among Patients With Acute Ischemic Stroke Undergoing Thrombectomy: A Systematic Review and Meta-analysis. JAMA. 2019 Oct 1;322(13):1283-1293. doi: 10.1001/jama.2019.11455. PubMed 31573636 ↗
  • Chabanne R, Geeraerts T, Begard M, Balanca B, Rapido F, Degos V, Tavernier B, Molliex S, Velly L, Verdonk F, Lukaszewicz AC, Perrigault PF, Albucher JF, Cognard C, Guyot A, Fernandez C, Masgrau A, Moreno R, Ferrier A, Jaber S, Bazin JE, Pereira B, Futier E; ANARLF NetworkAMETIS Study Group. Outcomes After Endovascular Therapy With Procedural Sedation vs General Anesthesia in Patients With Acute Ischemic Stroke: The AMETIS Randomized Clinical Trial. JAMA Neurol. 2023 May 1;80(5):474-483. doi: 10.1001/jamaneurol.2023.0413. PubMed 37010829 ↗
  • Maurice A, Eugene F, Ronziere T, Devys JM, Taylor G, Subileau A, Huet O, Gherbi H, Laffon M, Esvan M, Laviolle B, Beloeil H; GASS (General Anesthesia versus Sedation for Acute Stroke Treatment) Study Group and the French Society of Anesthesiologists (SFAR) Research Network. General Anesthesia versus Sedation, Both with Hemodynamic Control, during Intraarterial Treatment for Stroke: The GASS Randomized Trial. Anesthesiology. 2022 Apr 1;136(4):567-576. doi: 10.1097/ALN.0000000000004142. PubMed 35226737 ↗
  • Quintard H, Degos V, Mazighi M, Berge J, Boussemart P, Chabanne R, Figueiredo S, Geeraerts T, Launey Y, Meuret L, Olivot JM, Pottecher J, Rapido F, Richard S, Saleme S, Siguret-Depasse V, Naggara O, De Courson H, Garnier M. Anaesthetic and peri-operative management for thrombectomy procedures in stroke patients. Anaesth Crit Care Pain Med. 2023 Feb;42(1):101188. doi: 10.1016/j.accpm.2022.101188. Epub 2023 Jan 1. PubMed 36599377 ↗
  • Turc G, Bhogal P, Fischer U, Khatri P, Lobotesis K, Mazighi M, Schellinger PD, Toni D, de Vries J, White P, Fiehler J. European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute Ischaemic StrokeEndorsed by Stroke Alliance for Europe (SAFE). Eur Stroke J. 2019 Mar;4(1):6-12. doi: 10.1177/2396987319832140. Epub 2019 Feb 26. PubMed 31165090 ↗
  • Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46-e110. doi: 10.1161/STR.0000000000000158. Epub 2018 Jan 24. PubMed 29367334 ↗

Individual participant data

Plan to share: Yes — IPD that underlie results in a publication can be made available upon specific request from investigators.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2029, 39 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 39 months is above that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Nov 19, 2025
StartActual
Mar 24, 2026
Primary completionEst.
Jun 24, 2029
CompletionEst.
Jun 24, 2029
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07235514
Collaborators
PHRC, Ministry of Health France, STROKELINK, ANARLF Network
Responsible party
Sponsor
First posted
Nov 19, 2025
Start date
Mar 24, 2026
Primary completion
Jun 24, 2029 (estimated)
Completion
Jun 24, 2029 (estimated)
Last update
Sep 2, 2026

Study contacts

Lise Laclautre
Contact
promo_interne_drci@chu-clermontferrand.fr
334.73.754.963
Russell CHABANNE
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion